AMENDMENTS TO THE SPECIFICATION

In the Specification:

Please amend the paragraph beginning on page 2, line 28 and ending on page 2, line 32 as follows:

According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet Switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 3, line 20 and ending on page 4, line 19 as follows:

According to yet an additional aspect of the present invention there is provided An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still an additional aspect of the present invention there is provided An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to a further aspect of the present invention there is provided an oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html)

using default parameters.

According to yet a further aspect of the present invention there is provided A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters, thereby treating the Met-related disease in a subject.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 4, line 28 and ending on page 5, line 27 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the

LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters, thereby treating the IL-6-related disease in the subject.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 6, line 3 and ending on page 7, line 2 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 7, line 11 and ending on page 8, line 9 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 8, line 18 and ending on page 9, line 17 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html)

using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 9, line 26 and ending on page 10, line 24 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland

~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 11, line 1 and ending on page 11, line 32 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 12, line 9 and ending on page 13, line 7 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 13, line 14 and ending on page 14, line 14 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html)

using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 14, line 23 and ending on page 15, line 22 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland

~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraphs beginning on page 15, line 31 and ending on page 16, line 24 as follows:

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 24, line 23 and ending on page 24, line 29 as follows:

According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 27, line 25 and ending on page 27, line 31 as follows:

According to another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 29, line 20 and ending page 29, line 26 as follows:

According to yet another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 9 or 13, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 31, line 21 and ending on page 31, line 27 as follows:

According to still another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 33, line 23 and ending on page 33, line 29 as follows:

According to an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 21 or 25, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 35, line 26 and ending on page 35, line 32 as follows:

According to yet an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 37, line 20 and ending on page 38, line 2 as follows:

According to still an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 39, line 25 and ending on page 39, line 31 as follows:

According to a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html) using default parameters.

Please amend the paragraph beginning on page 41, line 24 and ending on page 41, line 30 as follows:

According to yet a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland ~~(http://www.ch.embnet.org/index.html)~~(http://wwwdotch.embnetdotorg/index.html)

using default parameters.

Please amend the paragraph beginning on page 53, line 3 and ending on page 53, line 10 as follows:

Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. (~~www.invitrogen.com~~ wwwdotinvitrogendotcom). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the trasgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter.

Please amend the paragraph beginning on page 72, line 24 and ending on page 72, line 28 as follows:

Human ESTs and cDNAs were obtained from NCBI GenBank version 126 (Oct 15 2001,~~www.ncbi.nlm.nih.gov/dbEST~~ wwwdotncbi.nlm.nihdotgov) and aligned to the human genome (NCBI assembled genomic sequence from Oct. 2001) using the LEADS clustering and assembly system as described in U.S. Pat. No. 6,625,545 and U.S. Pat. Appl. No. 10/426,002.

Please amend the paragraph beginning on page 74, line 13 and ending on page 74, line 22 as follows:

Each of the multiple nodes of the dendrogram is annotated by at least one keyword describing the node, and enabling literature and database text mining, such as by using publicly available text mining software. A list of keywords can be obtained from the GO Consortium ~~(www.geneontlogy.org)~~ (wwwdotgeneontlogydotorg). However, measures are taken to include as many keywords, and to include keywords which might be out of date. For example, for tissue annotation, a hierarchy is built using all available tissue/libraries sources available in the GenBank, while considering the following parameters: ignoring GenBank synonyms, building anatomical hierarchies, enabling flexible distinction

between tissue types (normal versus pathology) and tissue classification levels (organs, systems, cell types, etc.).

Please amend the paragraph beginning on page 76, line 10 and ending on page 76, line 22 as follows:

Data concerining therapies, indications and possible pharmacological activities of the polypeptides of the present invention was obtained from PharmaProject (PJB Publications Ltd 2003~~——http://www.pjbpubs.com/cms.asp?pageid=340~~ http://wwwdotpjbpubs.com/cms) and public databases, including LocusLink ~~(http://www.genelynx.org/cgi-bin/resource?res=locuslink)~~(http://wwwdotgenelynx.org/cgi-bin) and Swissprot ~~(http://www.ebi.ac.uk/swissprot/index.html)~~ (http://wwwdotebi.ac.uk/swissprot/index). Functional structural analysis of the polypeptides of the present invention was effected using Interpro domain analysis software (Interpro default parameters, the analyses that were run are HMMPfam, HMMSmart, ProfileScan, FprintScan, and BlastProdom). Subecllular localization was analysed using ProLoc software (Einat Hazkani-Covo, Erez Y. Levanon, Galit Rotman, Dan Graur, Amit Novik. Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in Saccharomyces, Drosophila and Caenorhabditis. Cell Biology International (in press).